<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00376805</url>
  </required_header>
  <id_info>
    <org_study_id>UMN-2005LS033</org_study_id>
    <secondary_id>UMN-0505M70037</secondary_id>
    <secondary_id>UMN-MT2005-08</secondary_id>
    <nct_id>NCT00376805</nct_id>
    <nct_alias>NCT00167193</nct_alias>
  </id_info>
  <brief_title>Allogeneic Natural Killer (NK) Cells in Patients With Advanced Metastatic Breast Cancer</brief_title>
  <official_title>Allogeneic Natural Killer Cells in Patients With Advanced Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masonic Cancer Center, University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Masonic Cancer Center, University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Giving chemotherapy before a donor natural killer (NK) cell infusion helps stop
      the growth of tumor cells. It also helps stop the patient's immune system from rejecting the
      donor's cells. Giving NK cells from a related donor may kill the tumor cells.

      PURPOSE: This study furthers the research of previous studies (MT2003-01 and MT2004-25) which
      were to determine a specific preparatory regimen (cyclophosphamide and fludarabine) could
      create an environment in which infused NK cells can grow and effectively treat patients with
      relapsed AML. This study will test the previous regimen in patients with breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We believe that administration of related allogeneic (donor) natural killer cells along with
      IL-2, rather than autologous natural killer cells will provide the most effective anticancer
      therapy in this setting, and wish to test this approach. To do this, we will select a related
      donor who is partially HLA-matched with the study subject, to increase the likelihood that
      donor natural killer cells will kill the subject's cancer cells. We will also give
      chemotherapy drugs to increase the subject's tolerance for the donor natural killer cells. We
      will test the use of donor natural killer (NK) cell infusions. The immune system has a
      special way that it sees and identifies cancer cells or foreign agents (like viruses). The
      subject's own NK cells may not attack their cancer because NK cells see the tumor cells as
      &quot;self&quot; (a coating on the cell surface identifies a cell as &quot;self&quot; or &quot;non-self&quot;). We have
      reason to believe that NK cells may not kill cancer cells because NK cells have special
      receptors that &quot;turn them off&quot; when they encounter cancer cells (by seeing them as &quot;self&quot;).
      We may be able to get around this problem by using donor NK cells. Finally, subjects will
      receive a dose of subcutaneous IL-2 3 times a week (for 2 weeks) which has been proven safe
      in our previous studies to stimulate the natural killer cells.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Withdrawn due to toxicity
  </why_stopped>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients Who Had Expansion of Natural Killer Cells</measure>
    <time_frame>Day 14</time_frame>
    <description>Successful Natural Killer (NK) cell expansion is defined as detection of an absolute circulating donor-derived NK cell count of &gt;100 cells/ul of whole blood 14 days after infusion with &lt;5% donor T and B cells in mononuclear population (in metastatic breast cancer patients).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients by Disease Response</measure>
    <time_frame>6 Months, 1 Year</time_frame>
    <description>Defined by the Response Evaluation Criteria in Solid Tumors (RECIST) criteria:
Complete Response (CR: Disappearance of all target lesions
Partial Response (PR): At least a 30% decrease in the sum of the longest diameter (LD) of target lesions
Stable Disease (SD): Neither sufficient shrinkage to qualify for PR or sufficient increase to qualify for PD
Progressive Disease (PD): At least a 20% increase in the sum of the LD of target lesions of appearance of one or more new lesions
of clinical benefit (CB; stable disease for greater than 6 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Who Died While on Study</measure>
    <time_frame>Within 100 days, After 100 days</time_frame>
    <description>Number of patients who died within 100 days and after 100 days of natural killer (NK) treatment with or without total body irradiation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Median Number of Days Patients Alive After Treatment</measure>
    <time_frame>First Day of Treatment Until Death</time_frame>
    <description>Calculated median number of days of survival (patients alive days after treatment).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>All Treated Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients with advanced metastatic breast cancer treated with natural killer cells after receiving fludarabine, cyclosphosphamide and total body irradiation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>administered intravenously 25 mg/m^2 times 5 doses</description>
    <arm_group_label>All Treated Patients</arm_group_label>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>administered intravenously 60 mg/kg days times 2 doses.</description>
    <arm_group_label>All Treated Patients</arm_group_label>
    <other_name>Endoxan, Cytoxan, Neosar, Procytox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total body irradiation</intervention_name>
    <description>200 cGy (gray) on day -1</description>
    <arm_group_label>All Treated Patients</arm_group_label>
    <other_name>radiation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Natural killer cell infusion</intervention_name>
    <description>Infused cell dose is within the range of 1.5-8.0 x 10^7/kg. Cell counts are based on total cells infused after the activation culture and washing determined on the morning of infusion.</description>
    <arm_group_label>All Treated Patients</arm_group_label>
    <other_name>NK cells</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Interleukin-2</intervention_name>
    <description>administered subcutaneously (10 MU) 3 times per week for 6 doses</description>
    <arm_group_label>All Treated Patients</arm_group_label>
    <other_name>IL-2</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Diagnosis of metastatic breast cancer that has progressed on or failed at least one
             salvage chemotherapy regimen for metastatic disease and that meets the following
             disease specific related criteria:

               -  Measureable metastatic disease per Response Evaluation Criteria In Solid Tumor
                  (RECIST) - bone only not eligible.

               -  Disease progression while receiving prior therapy with a hormonal agent (if
                  estrogen/progesterone receptor-positive) and/or trastuzumab (Herceptin®) (if
                  HER2-neu positive)

               -  Brain metastases allowed provided they are stable for ≥ 3 months after prior
                  treatment

          -  Related HLA-haploidentical natural killer cell donor available (by ≥ class I serologic
             typing)

          -  Male or female

          -  Performance status 50-100%

          -  Platelet count ≥ 80,000/mm³ (unsupported by transfusions)

          -  Hemoglobin ≥ 9 g/dL (unsupported by transfusions)

          -  Absolute neutrophil count ≥ 1,000/mm³ (unsupported by sargramostim [GM-CSF] or
             filgrastim [G-CSF])

          -  Creatinine ≤ 2.0 mg/dL

          -  Liver function tests &lt; 5 times normal

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  LVEF &gt; 40%*

          -  Pulmonary function &gt; 50%* (DLCO corrected AND FEV_1)

          -  No active infection (i.e., afebrile, off antibiotics, and no uninvestigated radiologic
             lesions)

        Exclusion Criteria:

          -  At least 3 days since prior prednisone or other immunosuppressive medications

          -  No other concurrent therapy for cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Miller, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Masonic Cancer Center, University of Minnesota</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sarah Cooley, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Masonic Cancer Center, University of Minnesota</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Masonic Cancer Center at University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2006</study_first_submitted>
  <study_first_submitted_qc>September 13, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2006</study_first_posted>
  <results_first_submitted>July 13, 2010</results_first_submitted>
  <results_first_submitted_qc>July 13, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 12, 2010</results_first_posted>
  <last_update_submitted>December 3, 2017</last_update_submitted>
  <last_update_submitted_qc>December 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IV breast cancer</keyword>
  <keyword>male breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Interleukin-2</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>NK Cells With or Without Total Body Irradiation</title>
          <description>Patients receiving natural killer cell infusion, fludarabine and cyclosphosphamide preparatory regimen, and with or without total body irradiation for treatment of metastatic breast cancer.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>NK Cells With or Without Total Body Irradiation</title>
          <description>Patients receiving natural killer cell infusion, fludarabine and cyclosphosphamide preparatory regimen, and with or without total body irradiation for treatment of metastatic breast cancer.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.1" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Who Had Expansion of Natural Killer Cells</title>
        <description>Successful Natural Killer (NK) cell expansion is defined as detection of an absolute circulating donor-derived NK cell count of &gt;100 cells/ul of whole blood 14 days after infusion with &lt;5% donor T and B cells in mononuclear population (in metastatic breast cancer patients).</description>
        <time_frame>Day 14</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NK Cells With or Without Total Body Irradiation</title>
            <description>Patients receiving natural killer cell infusion, fludarabine and cyclosphosphamide preparatory regimen, and with or without total body irradiation for treatment of metastatic breast cancer.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Had Expansion of Natural Killer Cells</title>
          <description>Successful Natural Killer (NK) cell expansion is defined as detection of an absolute circulating donor-derived NK cell count of &gt;100 cells/ul of whole blood 14 days after infusion with &lt;5% donor T and B cells in mononuclear population (in metastatic breast cancer patients).</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients by Disease Response</title>
        <description>Defined by the Response Evaluation Criteria in Solid Tumors (RECIST) criteria:
Complete Response (CR: Disappearance of all target lesions
Partial Response (PR): At least a 30% decrease in the sum of the longest diameter (LD) of target lesions
Stable Disease (SD): Neither sufficient shrinkage to qualify for PR or sufficient increase to qualify for PD
Progressive Disease (PD): At least a 20% increase in the sum of the LD of target lesions of appearance of one or more new lesions
of clinical benefit (CB; stable disease for greater than 6 months.</description>
        <time_frame>6 Months, 1 Year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NK Cells With or Without Total Body Irradiation</title>
            <description>Patients receiving natural killer cell infusion, fludarabine and cyclosphosphamide preparatory regimen, and with or without total body irradiation for treatment of metastatic breast cancer.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients by Disease Response</title>
          <description>Defined by the Response Evaluation Criteria in Solid Tumors (RECIST) criteria:
Complete Response (CR: Disappearance of all target lesions
Partial Response (PR): At least a 30% decrease in the sum of the longest diameter (LD) of target lesions
Stable Disease (SD): Neither sufficient shrinkage to qualify for PR or sufficient increase to qualify for PD
Progressive Disease (PD): At least a 20% increase in the sum of the LD of target lesions of appearance of one or more new lesions
of clinical benefit (CB; stable disease for greater than 6 months.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Stable Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Who Died While on Study</title>
        <description>Number of patients who died within 100 days and after 100 days of natural killer (NK) treatment with or without total body irradiation.</description>
        <time_frame>Within 100 days, After 100 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NK Cells With or Without Total Body Irradiation</title>
            <description>Patients receiving natural killer cell infusion, fludarabine and cyclosphosphamide preparatory regimen, and with or without total body irradiation for treatment of metastatic breast cancer.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Who Died While on Study</title>
          <description>Number of patients who died within 100 days and after 100 days of natural killer (NK) treatment with or without total body irradiation.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Died within 100 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Died after 100 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Median Number of Days Patients Alive After Treatment</title>
        <description>Calculated median number of days of survival (patients alive days after treatment).</description>
        <time_frame>First Day of Treatment Until Death</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NK Cells With or Without Total Body Irradiation</title>
            <description>Patients receiving natural killer cell infusion, fludarabine and cyclosphosphamide preparatory regimen, and with or without total body irradiation for treatment of metastatic breast cancer.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Median Number of Days Patients Alive After Treatment</title>
          <description>Calculated median number of days of survival (patients alive days after treatment).</description>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124" lower_limit="55" upper_limit="212"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All adverse events were collected up to patients' death (within 1 year of treatment).</time_frame>
      <group_list>
        <group group_id="E1">
          <title>NK Cells With or Without Total Body Irradiation</title>
          <description>Patients receiving natural killer cell infusion, fludarabine and cyclosphosphamide preparatory regimen, and with or without total body irradiation for treatment of metastatic breast cancer.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Bone marrow cellularity</sub_title>
                <description>Marrow aplasia</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Passenger lymphocyte syndrome</sub_title>
                <description>Hemolysis</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death - disease progression NOS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Death due to progressive disease</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" events="22" subjects_affected="4" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hemolytic anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="12" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Cardiac function LVEF</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="11" subjects_affected="4" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="26" subjects_affected="6" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="19" subjects_affected="6" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="46" subjects_affected="6" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <description>Includes arthralgia</description>
                <counts group_id="E1" events="16" subjects_affected="4" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="11" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <description>Includes pulmonary infiltrates</description>
                <counts group_id="E1" events="15" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="10" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Injection Site Reaction</sub_title>
                <counts group_id="E1" events="26" subjects_affected="6" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <description>Includes desquamation</description>
                <counts group_id="E1" events="30" subjects_affected="5" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Sweats</sub_title>
                <counts group_id="E1" events="16" subjects_affected="4" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sarah Cooley, MD</name_or_title>
      <organization>Masonic Cancer Center, University of Minnesota</organization>
      <phone>612-625-8474</phone>
      <email>cool0023@umn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

